Catalyst Pharmaceutical CPRX Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's accrued expenses and other liabilities?
- Catalyst Pharmaceutical (CPRX) reported accrued expenses and other liabilities of -$9.21M in Q1 2026.
- How has Catalyst Pharmaceutical's accrued expenses and other liabilities changed year-over-year?
- Catalyst Pharmaceutical's accrued expenses and other liabilities decreased by 260.8% year-over-year, from -$2.55M to -$9.21M.
- What is the long-term trend for Catalyst Pharmaceutical's accrued expenses and other liabilities?
- Over 3 years (2022 to 2025), Catalyst Pharmaceutical's accrued expenses and other liabilities has grown at a 13.8% compound annual growth rate (CAGR), from $16.39M to $24.16M.